NCT00212719

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P50-P75 for phase_3

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2003

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 21, 2005

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2006

Completed
Last Updated

October 11, 2012

Status Verified

October 1, 2012

Enrollment Period

2.9 years

First QC Date

September 13, 2005

Last Update Submit

October 10, 2012

Conditions

Keywords

ONO-5920, osteoporosis, bisphosphonate

Outcome Measures

Primary Outcomes (1)

  • Mean bone mineral density of the lumbar spine (L2-4 BMD)

Secondary Outcomes (1)

  • Bone mineral density at femur, fragility fractures, biochemical markers of bone turnover, lower back pain

Interventions

Eligibility Criteria

Age45 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A diagnosis in accordance with Criteria for the Diagnosis of Primary Osteoporosis.

You may not qualify if:

  • Patients having secondary osteoporosis or another condition that presents low bone mass.
  • Patients having findings that affect measurement of lumbar spinal bone mineral density by DXA
  • Patients that have been administered bisphosphonate derivatives.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone. 2009 Jun;44(6):1078-84. doi: 10.1016/j.bone.2009.02.016. Epub 2009 Mar 2.

MeSH Terms

Conditions

Osteoporosis

Interventions

YM 529

Condition Hierarchy (Ancestors)

Bone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Project Leader, ' Development Planning

    Ono Pharmaceutical Co. Ltd

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 21, 2005

Study Start

May 1, 2003

Primary Completion

April 1, 2006

Last Updated

October 11, 2012

Record last verified: 2012-10